Skip to content
10-Q

Quarterly Report

Protagenic Therapeutics, Inc.new PTIX

0001493152-26-009301

← back to feed
Filed
Mar 9, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2026 · Mar 5, 2026 1.81M sh
Stock Issued Q3 2026 · Dec 31, 2025 51.2K sh
Shares Diluted Q3 2026 · Dec 31, 2025 1.93M sh
Shares Diluted Q3 2026 · Dec 31, 2025 2.48M sh
Shares Diluted Q3 2026 · Dec 31, 2024 5.4M sh
Shares Diluted Q3 2026 · Dec 31, 2024 5.4M sh
Operating Cash Flow Q3 2026 · Dec 31, 2025 −$3.07M
Operating Cash Flow Q3 2026 · Dec 31, 2024 −$917.51K
Stockholders Equity Q3 2026 · Dec 31, 2025 −$2.39M
Stockholders Equity Q3 2026 · Sep 30, 2025 −$4.7M
Stockholders Equity Q3 2026 · Jun 30, 2025 −$3.97M
Stockholders Equity Q3 2026 · Mar 31, 2025 −$4.95M
Stockholders Equity Q3 2026 · Dec 31, 2024 −$3.32M
Stockholders Equity restated Q3 2026 · Sep 30, 2024 −$2.47M
Stockholders Equity restated Q3 2026 · Jun 30, 2024 −$1.75M
Stockholders Equity restated Q3 2026 · Mar 31, 2024 −$1.79M
Current Liabilities Q3 2026 · Dec 31, 2025 $6.82M
Current Liabilities Q3 2026 · Mar 31, 2025 $5.04M
Total Liabilities Q3 2026 · Dec 31, 2025 $6.82M
Total Liabilities Q3 2026 · Mar 31, 2025 $5.04M
Current Assets Q3 2026 · Dec 31, 2025 $2.3M
Current Assets Q3 2026 · Mar 31, 2025 $89.09K
Total Assets Q3 2026 · Dec 31, 2025 $4.43M
Total Assets Q3 2026 · Mar 31, 2025 $89.09K
Eps Diluted Q3 2026 · Dec 31, 2025 $1.14
Eps Diluted Q3 2026 · Dec 31, 2025 −$1.50
Eps Diluted Q3 2026 · Dec 31, 2024 −$0.16
Eps Diluted Q3 2026 · Dec 31, 2024 −$0.33
Eps Basic Q3 2026 · Dec 31, 2025 $1.14
Eps Basic Q3 2026 · Dec 31, 2025 −$1.50
Eps Basic Q3 2026 · Dec 31, 2024 −$0.16
Eps Basic Q3 2026 · Dec 31, 2024 −$0.33
Sga Expense Q3 2026 · Dec 31, 2025 $154.82K
Sga Expense Q3 2026 · Dec 31, 2025 $489.95K
Sga Expense Q3 2026 · Dec 31, 2024 $49.7K
Sga Expense Q3 2026 · Dec 31, 2024 $95.47K
Rd Expense Q3 2026 · Dec 31, 2025 $153.79K
Rd Expense Q3 2026 · Dec 31, 2025 $821.13K
Rd Expense Q3 2026 · Dec 31, 2024 $134.58K
Rd Expense Q3 2026 · Dec 31, 2024 $170.68K
Net Income Q3 2026 · Dec 31, 2025 $2.21M
Net Income Q3 2026 · Dec 31, 2025 −$3.72M
Net Income Q3 2026 · Sep 30, 2025 −$869.5K
Net Income Q3 2026 · Jun 30, 2025 −$5.06M
Net Income Q3 2026 · Dec 31, 2024 −$850.29K
Net Income Q3 2026 · Dec 31, 2024 −$1.76M
Net Income restated Q3 2026 · Sep 30, 2024 −$582.39K
Net Income restated Q3 2026 · Jun 30, 2024 −$324.36K
Operating Income Q3 2026 · Dec 31, 2025 −$925.1K
Operating Income Q3 2026 · Dec 31, 2025 −$4.38M
Operating Income Q3 2026 · Dec 31, 2024 −$401.4K
Operating Income Q3 2026 · Dec 31, 2024 −$1.08M
Revenue Q3 2026 · Dec 31, 2025 $0